Hydrocodone rescheduling in 2014

Hydrocodone rescheduling in 2014 moved combination painkillers such as Vicodin and Lortab from Schedule III to Schedule II, restricting refills and requiring more frequent contact with prescribers. In the book, the policy’s significance lies in the tension between controlling prescription supply and maintaining care: Tess Henry blamed the resulting scarcity of pills for her turn to heroin, while patients and advocates warned that tighter controls could burden people in pain and push some users toward street drugs.

The Rule and Its Rationale

The change took effect in October 2014. Under the new rules, prescriptions were limited to intervals of thirty days or less, with no refills; patients needing more medication had to return to their doctors for a new prescription. Before the change, prescriptions could be refilled automatically as many as five times, covering as much as six months. The book places that earlier practice in a period when narcotic prescriptions quadrupled between 1999 and 2010, as did deaths.

The rescheduling was controversial. Public opinion leaned in favor, at 52 percent, while 41 percent opposed it. Chronic-pain patients objected to the added expense and inconvenience, arguing that controls aimed at illegal use should not penalize people who used medication responsibly. Comments submitted to the Drug Enforcement Administration’s public-feedback website also warned that reduced access to prescription drugs could send people toward heroin and other street drugs. Those warnings did not establish that rescheduling would produce that outcome for every patient, but they identified a risk the book returns to through individual experience.

Tess Henry’s Shift from Pills

Tess’s opioid use began in 2012 after an urgent-care visit for bronchitis resulted in prescriptions for codeine cough syrup and hydrocodone for sore-throat pain. When the prescriptions ran out, she sought pills from dealers. She later described recognizing withdrawal symptoms—including jitteriness and diarrhea—after looking up what she had been taking. At first, she could obtain the drugs she wanted and snorted about five pills a day, including Dilaudid, Roxicodone, Lortab, or Opana.

Several months into that routine, the supply of pills dried up. Tess attributed the shortage to the Drug Enforcement Administration’s reclassification of hydrocodone-based drugs, which she said made pills harder for her dealer to obtain. The dealer offered heroin as a cheaper, more accessible substitute. Tess took it as she had taken crushed pills. Her account gives the policy a concrete human consequence, but it remains her explanation of the change in her supply; the book does not establish that rescheduling by itself caused her transition.

Supply Controls and Street-Level Adaptation

The surrounding evidence cautions against treating the rule as a single-cause explanation for the heroin crisis. The pathway from prescription opioids to heroin was already visible elsewhere in the book: users who began with prescriptions sometimes turned to dealers and resold part of their supply to pay for the next purchase, driven by the need to avoid the pain of withdrawal. Heroin networks were also established in the region before the 2014 change. Clifton “Lite” Lee had brought heroin into the Roanoke area from 2006, and by his 2008 sentencing prosecutors attributed to his network shipments of a thousand bags two or three times a week.

By 2013, another supply route was bringing heroin into Virginia’s I-81 corridor from New York. The book describes a distribution network that used young women traveling by bus and concealed heroin in snack containers; a shipment could contain 200 grams. These examples do not show that hydrocodone rescheduling created heroin markets. They show that street supply and distribution networks could meet demand as prescription access changed, against a background in which addiction, withdrawal, and resale already connected users to dealers.

Treatment Access and the Limits of Restriction

The book also places the rescheduling debate alongside substantial barriers to treatment. After Tess became pregnant, she entered the Life Center of Galax, one of the few Virginia facilities then accepting patients receiving medication-assisted treatment. She took Subutex, a form of buprenorphine used for some pregnant patients. Her treatment required a $6,500 deductible paid by her father, while the overall bill was $20,000, most of which private insurance covered. The account shows that finding a treatment provider able to accommodate medication was itself a constraint, distinct from the rules governing painkiller prescriptions.

Later, buprenorphine medication was covered by Tess’s insurance, but visits to her addiction doctor were cash-only: $700 up front, followed by visits costing $90 to $100 each, as often as four times a month. Federal rules then capped the number of patients a certified prescriber could treat at 100, before the cap rose to 275 later that year. The Hope Initiative, organized through the Bradley Free Clinic, used a five-page spreadsheet listing thirty-six rehabilitation and aftercare providers to help connect people with available care; its volunteers did not agree about medication-assisted treatment. These details reveal the gap between restricting access to one class of drugs and making effective treatment readily reachable.

The book’s later account of a Virginia Tech Carilion Research Institute pilot offers a contrast in approach: Warren Bickel received a $1 million grant to test faster transfers from emergency care to outpatient buprenorphine, including a newly approved monthly injection. The rescheduling story therefore does not end with a simple verdict for or against tighter controls. It shows a policy intended to limit prescription access meeting a landscape of established heroin supply, opioid dependence, uneven treatment capacity, and continuing disagreement over how care should be delivered.